Compile Data Set for Download or QSAR
Report error Found 48 Enz. Inhib. hit(s) with all data for entry = 11125
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506474(Ft-2102 | Olutasidenib | US11376246, Compound 1 | ...)
Affinity DataIC50: 1nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM195601(GSK321 | US11376246, Cpd ID GSK321 | US11576906, C...)
Affinity DataIC50: 3.80nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM195601(GSK321 | US11376246, Cpd ID GSK321 | US11576906, C...)
Affinity DataIC50: 4.80nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506474(Ft-2102 | Olutasidenib | US11376246, Compound 1 | ...)
Affinity DataIC50: 5.10nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50503260(CHEMBL4456610 | US11376246, Cpd ID I-27 | US115769...)
Affinity DataIC50: 10nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50503280(CHEMBL4469055 | US11376246, Cpd ID I-26 | US115769...)
Affinity DataIC50: 10nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506474(Ft-2102 | Olutasidenib | US11376246, Compound 1 | ...)
Affinity DataIC50: 10nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132L](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506474(Ft-2102 | Olutasidenib | US11376246, Compound 1 | ...)
Affinity DataIC50: 10nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132S](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506474(Ft-2102 | Olutasidenib | US11376246, Compound 1 | ...)
Affinity DataIC50: 10nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM363689(US9850277, Compound 176 | US10682352, Compound AG1...)
Affinity DataIC50: 12nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM363689(US9850277, Compound 176 | US10682352, Compound AG1...)
Affinity DataIC50: 13nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM404661(US10344004, Test compound Table 3 | US10442772, Ex...)
Affinity DataIC50: 15nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM404661(US10344004, Test compound Table 3 | US10442772, Ex...)
Affinity DataIC50: 15nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50279397(CHEMBL4169151 | US11376246, Cpd ID IDH889 | US1157...)
Affinity DataIC50: 20nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506474(Ft-2102 | Olutasidenib | US11376246, Compound 1 | ...)
Affinity DataIC50: 21.2nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM550706(US11376246, Cpd ID AG-881 | US11576906, Compound A...)
Affinity DataIC50: 22nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM550706(US11376246, Cpd ID AG-881 | US11576906, Compound A...)
Affinity DataIC50: 22nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50279396(CHEMBL4172087 | US11376246, Cpd ID IDH305 | US1157...)
Affinity DataIC50: 27nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50279396(CHEMBL4172087 | US11376246, Cpd ID IDH305 | US1157...)
Affinity DataIC50: 28nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132G](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506474(Ft-2102 | Olutasidenib | US11376246, Compound 1 | ...)
Affinity DataIC50: 50nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506474(Ft-2102 | Olutasidenib | US11376246, Compound 1 | ...)
Affinity DataIC50: 50nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50503263(CHEMBL4464313 | US11376246, Cpd ID I-23 | US115769...)
Affinity DataIC50: 55nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506482(CHEMBL4547257 | US11376246, Cpd ID I-1 | US1157690...)
Affinity DataIC50: 55nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM550719(US11376246, Cpd ID I-22 | US11576906, Compound I-2...)
Affinity DataIC50: 55nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM550721(US11376246, Cpd ID I-25 | US11576906, Compound I-2...)
Affinity DataIC50: 55nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506480(CHEMBL4437754 | US11376246, Cpd ID I-20 | US115769...)
Affinity DataIC50: 55nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50279397(CHEMBL4169151 | US11376246, Cpd ID IDH889 | US1157...)
Affinity DataIC50: 72nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM550724(US11376246, Cpd ID I-29 | US11576906, Compound I-2...)
Affinity DataIC50: 100nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM550724(US11376246, Cpd ID I-29 | US11576906, Compound I-2...)
Affinity DataIC50: 100nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50503260(CHEMBL4456610 | US11376246, Cpd ID I-27 | US115769...)
Affinity DataIC50: 100nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50503280(CHEMBL4469055 | US11376246, Cpd ID I-26 | US115769...)
Affinity DataIC50: 100nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50503263(CHEMBL4464313 | US11376246, Cpd ID I-23 | US115769...)
Affinity DataIC50: 100nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM550719(US11376246, Cpd ID I-22 | US11576906, Compound I-2...)
Affinity DataIC50: 100nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506480(CHEMBL4437754 | US11376246, Cpd ID I-20 | US115769...)
Affinity DataIC50: 100nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506474(Ft-2102 | Olutasidenib | US11376246, Compound 1 | ...)
Affinity DataIC50: 114nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506476(CHEMBL4547484 | US11376246, Cpd ID I-2 | US1157690...)
Affinity DataIC50: 550nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM550717(US11376246, Cpd ID I-11 | US11576906, Compound I-1...)
Affinity DataIC50: 550nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM550716(US11376246, Cpd ID I-6 | US11576906, Compound I-6 ...)
Affinity DataIC50: 550nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506477(CHEMBL4456162 | US11376246, Cpd ID I-5 | US1157690...)
Affinity DataIC50: 550nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506483(CHEMBL4446598 | US11376246, Cpd ID I-3 | US1157690...)
Affinity DataIC50: 550nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506474(Ft-2102 | Olutasidenib | US11376246, Compound 1 | ...)
Affinity DataIC50: 922nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetIsocitrate dehydrogenase [NADP], mitochondrial [R172K](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506474(Ft-2102 | Olutasidenib | US11376246, Compound 1 | ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP], mitochondrial [R140Q](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506474(Ft-2102 | Olutasidenib | US11376246, Compound 1 | ...)
Affinity DataIC50: 4.00E+3nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM550717(US11376246, Cpd ID I-11 | US11576906, Compound I-1...)
Affinity DataIC50: 1.00E+4nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506476(CHEMBL4547484 | US11376246, Cpd ID I-2 | US1157690...)
Affinity DataIC50: 1.00E+4nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM550716(US11376246, Cpd ID I-6 | US11576906, Compound I-6 ...)
Affinity DataIC50: 1.00E+4nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506477(CHEMBL4456162 | US11376246, Cpd ID I-5 | US1157690...)
Affinity DataIC50: 1.00E+4nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM50506483(CHEMBL4446598 | US11376246, Cpd ID I-3 | US1157690...)
Affinity DataIC50: 1.00E+4nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
Go to US Patent